Merck KGaA Plays On Multiple Initiatives; Aims For 30% Growth In Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Contrary to what most global CEOs would say about challenges confronting the global pharmaceutical industry, Karl-Ludwig Kley, chairman of the $12.28 billion German chemicals and pharmaceuticals conglomerate Merck KGaA, says he doesn't believe the pharma business model is broken, despite dwindling R&D pipelines, increasing spend and diving sales as fewer blockbusters make it to market